This is a prospective, multi-center, single arm, open label, non-randomized study to evaluate the ability of \[68Ga\]FAPI-46 to detect FAP expressing cells in patients with resectable or borderline resectable PDAC. The \[68Ga\]FAPI-46 PET scans will be acquired after initial staging using institutional standard methods. If the participant is prescribed neoadjuvant therapy, a second \[68Ga\]FAPI-46 PET scan will be performed within 21 days prior to planned surgical resection. This will be followed by histopathology and IHC analyses and comparison to resected PDAC tumor specimens.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
63
\[68Ga\]-FAPI-46 is a radioactive diagnostic agent indicated for use with Positron Emission Tomography (PET) imaging for the detection of Fibroblast Activation Protein (FAP) positive cancer cells and cancer-associated fibroblasts (CAF) in patients with pancreatic ductal adenocarcinoma (PDAC).
University of California Los Angeles (UCLA) Health
Los Angeles, California, United States
BAMF Health
Grand Rapids, Michigan, United States
Mayo Clinic
Rochester, Minnesota, United States
NYU Langone Health
New York, New York, United States
Sensitivity of [68Ga]FAPI-46 PET Imaging to Detect PDAC, Using Histopathology as Truth Standard
Sensitivity was defined as the proportion of participants with histopathology-confirmed PDAC who had a positive \[⁶⁸Ga\]FAPI-46 PET result for the primary lesion. Sensitivity was calculated by comparing positive and negative \[⁶⁸Ga\]FAPI-46 PET findings with the corresponding histopathology results, using a single readable PET image matched to its reference histopathology assessment. Sensitivity was calculated as A / (A + C), where A represents true-positive findings and C represents false-negative findings. Higher sensitivity indicates a greater ability of \[⁶⁸Ga\]FAPI-46 PET to detect FAP-expressing disease and a lower likelihood of false-negative results, thereby reflecting the effectiveness of the imaging modality relative to the histopathological reference standard.
Time frame: Day 1
Correlation Between [⁶⁸Ga]FAPI-46 PET Uptake (SUVmax) and IHC Staining Intensity (H-score) in FAP-positive Lesions
The association between \[⁶⁸Ga\]FAPI-46 PET uptake, measured by maximum standardized uptake value (SUVmax), and FAP expression, assessed by H-score from histopathology, was evaluated. The relationship between SUVmax and H-score was assessed using the Spearman rank correlation coefficient, with corresponding 95% confidence intervals, in participants with evaluable PET imaging and histopathology results may not be linear owing in part to the H score ceiling of 300. All available paired PET and H-score measurements were included; when both pre- and post-neoadjuvant therapy data were available, each time point was analyzed separately. Spearman's rho was selected because it assesses monotonic relationships between ordinal or continuous variables and does not assume linearity, which may not be appropriate for the relationship between SUVmax and H-score.
Time frame: Day 1
Sensitivity of [68Ga]FAPI-46 PET to Detect FAP-expressing Cells Using H-score as Standard of Truth
Sensitivity was defined as the proportion of participants with IHC confirmed FAP-expressing cells who had a positive \[68Ga\]FAPI-46 PET result for the primary lesion. Sensitivity was calculated as A / (A + C), where A represents true positive findings and C represents false negative findings. Higher sensitivity indicates a greater ability of \[68Ga\]FAPI-46 PET to detect IHC confirmed FAP expression and a lower likelihood of false negative results, thereby reflecting the effectiveness of the imaging modality relative to the IHC reference standard. Sensitivity was presented considering IHC-positive results using 3 IHC cut-off values: \> 50: Overall positive versus negative expression; \> 100: Moderate to high expression and \> 200: High expression only.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Day 1
Specificity of [68Ga]FAPI-46 PET to Detect FAP-expressing Cells Using H-score as Standard of Truth
Specificity was defined as the proportion of participants without IHC-confirmed FAP-expressing cells who had a negative \[68Ga\]FAPI-46 PET result for the primary lesion. Specificity was calculated by comparing positive and negative \[68Ga\]FAPI-46 PET findings with the corresponding IHC results, using a single readable PET image matched to its reference IHC assessment. Specificity was calculated as D / (B + D), where B represents false-positive findings and D represents true-negative findings. PET results were compared with the corresponding IHC reference assessment using a single readable PET image per participant. Specificity was evaluated considering IHC-positive results using 3 IHC cut-off values \> 50: Overall positive versus negative expression; \> 100: Moderate to high expression and \> 200: High expression only.
Time frame: Day 1
Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs
An AE is any untoward medical occurrence in a clinical study participant whether or not considered related to the study intervention. A TEAE is any AE that occurs after receipt of one or more doses of study drug through the end of study for that participant. A SAE is defined as any untoward medical occurrence that, at any dose: results in death or is life-threatening or requires inpatient hospitalization or prolongation of existing hospitalization or results in persistent disability/incapacity or is a congenital anomaly/birth defect or is a medically significant / important event or reaction.
Time frame: Up to 2 years